The discovery that constitutive ABL kinase activity is sufficient and necessary to cause CML laid the foundation for development of imatinib as a target-directed therapy1, 2. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.